EcoDrugPlus

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSBTAG00000006378
Gene Symbol: RIPK1
33 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSBTAG00000002883
Gene Symbol: RPTOR
21 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Renin

Ensembl ID : ENSBTAG00000021333
Gene Symbol: REN
3 Enzyme and pathways 5 Cross references
232 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSBTAG00000000570
Gene Symbol: RET
8 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSBTAG00000012500
Gene Symbol: RARA
14 Enzyme and pathways 5 Cross references
343 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSBTAG00000011518
Gene Symbol: RARB
7 Enzyme and pathways 5 Cross references
463 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSBTAG00000007592
Gene Symbol: RARG
7 Enzyme and pathways 5 Cross references
463 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSBTAG00000017851
Gene Symbol: RXRA
41 Enzyme and pathways 5 Cross references
260 Possible Orthologues:

Retinoid X Receptor Beta

Ensembl ID : ENSBTAG00000000602
Gene Symbol: RXRB
10 Enzyme and pathways 5 Cross references
227 Possible Orthologues:

Retinoid X Receptor Gamma

Ensembl ID : ENSBTAG00000016801
Gene Symbol: RXRG
7 Enzyme and pathways 5 Cross references
289 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSBTAG00000019494
Gene Symbol: RPL10A
15 Enzyme and pathways 5 Cross references
179 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSBTAG00000020905
Gene Symbol: RPL11
15 Enzyme and pathways 5 Cross references
227 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).